Alnylam Pharma (ALNY) Stock Price & Analysis
ALNY Stock Chart & Stats
- Day’s Range
- MXN 3,201.29 - MXN 3,201.29
- 52-Week Range
- MXN 3,201.29 - MXN 8,380.00
- Previous Close
- MXN 3,240.01
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 415.30B
- Enterprise Value
- MXN 33.47B
- Total Cash (Recent Filing)
- MXN 3.59B
- Total Debt (Recent Filing)
- MXN 1.26B
- Price to Earnings (P/E)
- 8.1
- Beta
- 0.64
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 32.97
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
TTR Franchise Growth
Rapid growth in the core TTR franchise demonstrates strong demand for Alnylam’s marketed RNAi medicines and expanding commercial reach. Continued uptake, particularly in ATTR cardiomyopathy, can support durable revenue scaling and strengthen the company’s position in a growing specialty-care market.
Commercial Adoption And Access
Meaningful prescription share combined with broad reimbursement and distribution access gives AMVUTTRA a strong platform for continued adoption. The established prescriber base, infusion network, and home-treatment options can support patient persistence and reduce barriers to long-term commercialization.
Cash Generation
Positive operating cash flow and strong free cash flow provide internal funding for clinical development, commercialization, and business expansion. This financial capacity reduces reliance on external financing while supporting Alnylam’s ability to advance a broad pipeline and absorb development costs.
Bears Say
Slower Patient Conversion
Slower conversion of physician interest into patient starts could limit near-term growth in the ATTR cardiomyopathy franchise. If newer prescribers continue to have fewer diagnosed patients or maintain existing treatment habits, commercial investment may produce a slower and less predictable revenue ramp.
Reimbursement And Access Pressure
Reimbursement uncertainty and tighter Medicare Advantage access can directly affect treatment initiation, pricing, and gross-to-net revenue. These policy-driven barriers may make demand conversion less predictable and could constrain adoption even where the product has demonstrated clinical value.
Gross Margin Pressure
A lower product margin indicates that revenue growth is not translating fully into incremental profitability as royalty obligations rise with AMVUTTRA sales. Persistent margin pressure could reduce operating leverage, constrain cash available for pipeline investment, and temper the earnings benefit of commercial expansion.
ALNY FAQ
What was Alnylam Pharma’s price range in the past 12 months?
What is Alnylam Pharma’s market cap?
When is Alnylam Pharma’s upcoming earnings report date?
How were Alnylam Pharma’s earnings last quarter?
Is Alnylam Pharma overvalued?
Does Alnylam Pharma pay dividends?
What is Alnylam Pharma’s EPS estimate?
How many shares outstanding does Alnylam Pharma have?
What happened to Alnylam Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alnylam Pharma?
What is the TipRanks Smart Score and how is it calculated?
Alnylam Pharma Stock Smart Score
Company Description
Alnylam Pharma
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Website
- www.alnylam.com
- Address
- 675 West Kendall Street, Cambridge, MA, 02142, US
Alnylam Pharma (ALNY) Earnings & Revenues
ALNY Company Deck
ALNY Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, with strong product and TTR revenue growth, expanding AMVUTTRA adoption, broad patient access, encouraging brezosiran data, a growing pipeline, profitability, and substantial cash generation. However, management acknowledged that AMVUTTRA demand growth and conversion of physician engagement into patient starts are slower than expected, while 340B policy uncertainty, Medicare Advantage access changes, lower collaboration revenue, lower gross margin, and the need to enlarge the TRITON-CM study remain challenges.
View all MX:ALNY earnings summariesALNY Net sales Breakdown
- 67.90% Net product revenues
- 29.87% Net revenues from collaborations
- 2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 0 | 15 |
| Technical Analysis | 4 | 0 | 3 |
| Moving Averages | 0 | 0 | 12 |
